|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||6.37 - 6.46|
|52-week range||6.37 - 6.46|
|Beta (5Y monthly)||0.98|
|PE ratio (TTM)||1.92|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
It's hard for any stock to deliver positive gains while the market is falling. Molecular Partners' (NASDAQ: MOLN) shares have skyrocketed more than 40% year to date. On Jan. 10, Molecular Partners and Novartis announced positive results from their Empathy phase 2 study of ensovibep in treating acute COVID-19 patients.
Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.